Urinary Urgency: A Symptom In Need Of A Cure

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology. 2003;61:37–49. doi:10.1016/s0090-4295(02)02243-412559262
   PubMed Web of Science ®Google Scholar
• Starkman JS, Dmochowski RR. Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn. 2008;27(1):13–21. doi:10.1002/nau.2047217671973
   PubMed Web of Science ®Google Scholar
• Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005;95(3):335–340. doi:10.1111/j.1464-410X.2005.05294.x15679789
   PubMed Web of Science ®Google Scholar
• Cambronero Santos J, Errando Smet C. Prevalence of storage lower urinary tract symptoms in male patients attending a Spanish urology office. Urinary urgency as predictor of quality of life. Actas Urol Esp. 2016;40(10):621–627. doi:10.1016/j.acuro.2016.04.01227345257
   PubMed Web of Science ®Google Scholar
• Arya NG, Weissbart SJ, Xu S, Bhavsar R, Rao H. Quantitative changes in cerebral perfusion during urinary urgency in women with overactive bladder. Biomed Res Int. 2017;2017:2759035. doi:10.1155/2017/275903528904950
   PubMed Web of Science ®Google Scholar
• Coyne KS, Harding G, Jumadilova Z, Weiss JP. Defining urinary urgency: patient descriptions of “gotta go”. Neurourol Urodyn. 2012;31(4):455–459. doi:10.1002/nau.2124222275170
   PubMed Web of Science ®Google Scholar
• Chapple C, Schneider T, Haab F, et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int. 2014;114:418–426. doi:10.1111/bju.1267824552358
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204–1212. doi:10.1016/j.eururo.2007.07.00917651893
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011;107:1432–1440. doi:10.1111/j.1464-410X.2010.09640.x20860717
   PubMed Web of Science ®Google Scholar
• Dubeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled trial. J Urol. 2014;191:395–404. doi:10.1016/j.juro.2013.08.02723973522
   PubMed Web of Science ®Google Scholar
• Tubaro A, Heesakkers J, Cornu JN, Robinson D. Expert opinion on three clinical cases with a common urgent problem: urge urinary incontinence. Case Rep Urol. 2018;2018(16):8567436. doi:10.1155/2018/876854930410813
   PubMedGoogle Scholar
• Moyson J, Legrand F, Vanden Bossche M, Quackels T, Roumeguère T. Hyperactivité vésicale idiopathique: efficacité et tolerance des traitements pharmacologiques: revue de la littérature [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: a systematic review of the literature]. Prog Urol. 2017;27(4):203–228. ( French). doi:10.1016/j.purol.2016.12.01128228331
   PubMed Web of Science ®Google Scholar
• Kistler KD, Xu Y, Zou KH, Ntanios F, Chapman DS, Luo X. Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: an assessment of trial quality. Neurourol Urodyn. 2018;37(1):54–66. doi:10.1002/nau.2330928763112
   PubMed Web of Science ®Google Scholar
• Herbison P, McKenzie JE. Which anticholinergic is best for people with overactive bladders? A network meta-analysis. Neurourol Urodyn. 2019;38(2):525–534. doi:10.1002/nau.2389330575999
   PubMed Web of Science ®Google Scholar
• Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71(5):839–843. doi:10.1016/j.urology.2007.12.01718342923
   PubMed Web of Science ®Google Scholar
• Cardozo L, Khullar V, Wang JT, Guan Z, Sand PK. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010;106(6):816–821. doi:10.1111/j.1464-410X.2010.09202.x20151972
   PubMed Web of Science ®Google Scholar
• Heesakkers J, Espuña Pons M, Toozs Hobson P, Chartier-Kastler E. Dealing with complex overactive bladder syndrome patient profiles with a focus on fesoterodine: in or out of the EAU guidelines? Res Rep Urol. 2017;9:209–218. doi:10.2147/RRU.S14674629184855
   PubMed Web of Science ®Google Scholar
• Toviaz® (fesoterodine fumarate) [prescribing information]. UK Available from: http://www.medicines.org.uk/emc/medicine/20928 Accessed 522, 2019.
   Google Scholar
• Kerdraon J, Robain G, Jeandel C, et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly. Prog Urol. 2014;24(11):672–681. doi:10.1016/j.purol.2014.06.00325214448
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61(2):185–193. doi:10.1111/jgs.1208823350833
   PubMed Web of Science ®Google Scholar
• Kay GG, Maruff P, Scholfield D, et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad Med. 2012;124(3):7–15. doi:10.3810/pgm.2012.05.2543
   PubMed Web of Science ®Google Scholar
• 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019. doi:10.1111/jgs.15767
   Web of Science ®Google Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315. doi:10.1136/bmj.k131529695481
   PubMed Web of Science ®Google Scholar
• Salahudeen MS, Chyou TY, Nishtala PS. Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS One. 2016;11:e0151084. doi:10.1371/journal.pone.015108426999286
   PubMed Web of Science ®Google Scholar
• Wagg A. Constant anticholinergic drug use among elderly linked to higher dementia risk. Available from: http://uroweb.org/constant-anticholinergic-drug-use-among-elderly-linked-to-higher-dementia-risk Accessed 522, 2019.
   Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167–174. doi:10.1111/j.1755-5949.2011.00248.x22070184
   PubMed Web of Science ®Google Scholar